 Investment analysts at Roth Capital started coverage on shares of Entasis Therapeutics NASDAQ:ETTX in a report released on Monday, The Fly reports. The brokerage set a buy rating and a 9.00 price target on the stock. Roth Capitals price target would indicate a potential upside of 206.12 from the companys previous close. A number of ... 